Access with evidence development: An approach to introducing promising new technologies into healthcare;L'accessibilité par la production de preuves: Une démarche pour intégrer de nouvelles technologies prometteuses aux soins de santé

Healthcare Management Forum

Volumn 24, Issue 2, 2011, Pages 42-48

  Menon, Devidas ^a   Stafinski, Tania ^a   Nardelli, Alexa ^a   Jackson, Terri ^a   Jhamandas, Jack ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS WITH EVIDENCE DEVELOPMENT; ARTICLE; CHECKLIST; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE NEED; HEALTH CARE ORGANIZATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; MEDICAL TECHNOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 79960968780     PISSN: 08404704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hcmf.2011.02.008     Document Type: Article

References (18)

1. Stanbrook MB, Hebert PC. Access to treatment for multiple sclerosis must be based on science, not hope. Consulté le 22 mars 2011, à l'adresse www.cmaj.ca/cgi/rapidpdf/cmaj.100835v1.
2. Malagoni AM, Galeotti R, Menegatti E et coll. Is chronic fatigue the symptom of venous insufficiency associated with multiple sclerosis? A longitudinal pilot study. Int Angiol. 2010;29:176-182.
3. Zamboni P, Galeotti R, Menegatti E et coll. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg. 2009;50:1348-1358.
4. Zamboni P, Menegatti E, Weinstock-Guttman B et coll. CSF dynamics and brain volume in multiple sclerosis are associated with extracranial venous flow anomalies: a pilot study. Int Angiol. 2010;29:140-18.
5. Zivadinov R, Schirda C, Dwyer MG et coll. Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study. Int Angiol. 2010;29:158-175.
6. e Parlement. 2010;145(062).
7. Briggs A, Ritchie K, Fenwick E et coll. Access with evidence development in the UK: past experience, current initiatives and future potential. Pharmacoeconomics. 2010;28:163-170.
8. Chapman S, Reeve E, Rajaratnam G et coll. Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care. Br Med J. 2003;326:707-709. (Pubitemid 36390459)
9. McCabe CJ, Stafinski T, Edlin R et coll. Access with evidence development schemes: a framework for description and evaluation. Pharmacoeconomics. 2010;28:143-152.
10. Menon D, McCabe CJ, Stafinski T et coll. Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit. Pharmacoeconomics. 2010;28:109-111.
11. Miller FG, Pearson SD. Coverage with evidence development - ethical issues and policy implications. Med Care. 2008; 46:746-751.
12. Mohr PE, Tunis SR. Access with evidence development: the US experience. Pharmacoeconomics. 2010;28:153-162.
13. Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ. 2010;340:c1672.
14. Stafinski T, McCabe CJ, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems. Pharmacoeconomics. 2010;28:113-142.
15. Khan O, Filippi M, Freedman MS et coll. Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol. 2010;67:286-290.
16. Wolf BR, Buckwalter JA. Randomized surgical trials and "sham" surgery: relevance to modern orthopaedics and minimally invasive surgery. Iowa Orthop J. 2006;26:107-11.
17. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.
18. er et 2 avril 2010; Washington, DC.